From: Epigenetics in breast cancer: what's new?
Inhibitor
Major targeted enzymes
Changed histone marks
Citation
Chaetocin1
Suv39h1, G9a
H3K9
[48]
DZNep
EZh2
H3K27
[49]
Novobiocin
SMYD3
H3K4
[51]
Trancylpromine, clorgyline, pargyline
LSD1, LSD2
H3K4, H3K9
[35, 52, 53]
Polyamine analogs
LSD1
[54, 55]
N-oxalylglycine
JMJD2A, JMJD2C
H3K9, H3K36
[57]
